Arcturus reports positive ARCT-810 Phase 2 data, unveils LUNAR 2.0 platform, to acquire myNEO

Arcturus Therapeutics Holdings Inc.

ARCT-810 generally safe; reduced/maintained fasting ammonia and glutamine in OTC deficiency patients.
LUNAR 2.0 shows 40-fold higher hEPO and 38-fold higher hOTC expression vs LUNAR 1.0 in NHP studies.
FDA feedback supports ARCT-2601 integration into ongoing Phase 2 study by year-end 2026.
Definitive agreement to acquire myNEO; closing expected in October 2026.
New programs for PKU and Gout announced using LUNAR 2.0.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.